Why IMU is a multi multi bagger, page-27958

they are now to reporting these also how desperate RAC, soon you will see me in your forums

"HERVaxx Does Next to Nothing" is a atrocious statement, Early trials are often designed to identify safety, dosing, and preliminary efficacy signals. HER-Vaxx’s ability to produce any different outcomes compared to standard care is an achievement in itself at this stage.In terms of statistical and practical Significance just accounting for survival bias in analyses is enough to clarify the treatment’s efficacy, but even with the current interpretation and available data, HER-Vaxx’s lower toxicity and potential for improved quality of life is itself a meaningful contributions to cancer therapy you just deliberately underestimate the innovation and potential of HER-Vaxx, both in terms of its patent structure and clinical application, patents demonstrate progression in positive direction , while the clinical results, suggests a valuable benefits which warrants go all in and explore further.

regarding your patent criticism,

give it up else you would be doing better in life, patents normally represent advancements in formulation and delivery technology, such as the use of the CRM-197 carrier protein and water-in-oil adjuvants. These are not trivial "small adjustments"; they address specific challenges like immunogenicity and effectiveness, they often qualify as non obvious improvements under patent law.